Procyon Advisors LLC increased its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 12.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,854 shares of the company's stock after purchasing an additional 4,159 shares during the quarter. Procyon Advisors LLC's holdings in AstraZeneca were worth $2,782,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Confluence Investment Management LLC purchased a new position in shares of AstraZeneca in the first quarter valued at $27,000. Banque Transatlantique SA acquired a new stake in AstraZeneca in the fourth quarter valued at $26,000. Mascagni Wealth Management Inc. acquired a new stake in AstraZeneca in the fourth quarter valued at $29,000. CoreCap Advisors LLC raised its holdings in AstraZeneca by 31.8% in the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares in the last quarter. Finally, Financial Management Professionals Inc. raised its holdings in AstraZeneca by 34.4% in the first quarter. Financial Management Professionals Inc. now owns 781 shares of the company's stock valued at $57,000 after acquiring an additional 200 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Stock Up 0.7%
AZN traded up $0.53 during trading on Friday, hitting $72.88. The company had a trading volume of 2,453,922 shares, compared to its average volume of 5,203,549. The company has a market cap of $226.02 billion, a PE ratio of 32.25, a P/E/G ratio of 1.42 and a beta of 0.38. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The business has a 50-day moving average of $69.32 and a 200-day moving average of $70.01. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period last year, the firm posted $2.06 EPS. The company's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. Finally, UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $85.00.
Read Our Latest Stock Report on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
